Colon cancer, which is the third most common cancer found in American men and women, may soon be on the decline thanks to a new Israeli company.
Bio Mark, formed by holding company Micromedic Technologies, has developed a colon cancer screening test which promises to catch the early stages of colon cancer in those who have not yet done preliminary tests. The test is expected to obtain FDA approval within a year.
According to Bio Mark, its new test, which is given as part of a routine blood screening, can correctly identify adenomas, the colon polyps which may become colon cancer, at a success rate of over 80 percent. The test is based on the research of Nadir Arber, a professor of medicine and gastroenterology at Tel Aviv University, who heads the Cancer Prevention Unit at the Tel Aviv Medical Center.
On top of its accuracy and easy, Bio Mark's colon cancer test is also much more affordable than its predecessors. While other tests for detecting polyps are both painful and expensive (about $1,500), Bio Mark's test will cost between $50 and $100, and requires a regular blood sample.
David Solomon, CEO of Bio Mark, told Israel21c that while only two out of five American citizens undergo colon cancer screenings, one out of four people over the age of 50 harbor polyps in the intestine. According to Solomon, 95 percent of colon cancer can be attributed to polyps.
Solomon believes Bio Mark's new test will encourage more people to get tested for adenomas, and will thereby save many lives.
Bio Mark, based in Ramat Gan, is also developing a drug to fight colon cancer. Bio Mark's sister company, BioGan, is now developing a kit for early detection of breast and ovarian cancer in women.